Pipeline
Targeting Conditions Where Current Treatments Fail to Address Unmet Medical Needs
We have a portfolio of clinical and preclinical compounds that we believe are best-in-class due to their unique mechanism of action and where human proof of concept has been established for the compound or the target.
| Candidate | Mechanism | Indications | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|
| CERC-301 | NR2B specific NMDA antagonist | Orphan Neurological Indications |
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
| CERC-611 | AMPA-TARP-γ8 antagonist | Adjunctive treatment of partial-onset seizures in epilepsy |
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
| CERC-406 | Selective, brain penetrant COMT inhibitor | Residual cognitive impairment symptoms |
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Market Need: Addressing the Continued CNS Burden
Central nervous system (CNS) disorders are associated with the highest medical treatment and long-term care costs and overall economic burden.
Patient Resources
Learn more about the CNS disorders we’re targeting, as well as contact information for help hotlines.
View Patient Resources